Drug Profile
Research programme: osteoarthritis therapy - Chugai/Denka Company Limited
Alternative Names: DK 226; methotrexate-hyaluronic acid conjugateLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical; Denki Kagaku Kogyo
- Developer Chugai Pharmaceutical; Denka Company Limited
- Class Drug conjugates; Polysaccharides; Pterins
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoarthritis in Japan (Intra-articular, Injection)
- 10 Apr 2008 Preclinical trials in Osteoarthritis in Japan (Intra-articular)